SCI Abstract

search
Kidney function is associated with plasma ATN biomarkers among Hispanics/Latinos: SOL-INCA and HCHS/SOL results
Kidney function is associated with plasma ATN biomarkers among Hispanics/Latinos: SOL-INCA and HCHS/SOL results
Plasma amyloid-tau-neurodegeneration (ATN) biomarker levels may be influenced by non-brain systems, such as kidney functio...
A longitudinal study of the 5xFAD mouse retina delineates Amyloid beta (Aβ)-mediated retinal pathology from age-related changes
A longitudinal study of the 5xFAD mouse retina delineates Amyloid beta (Aβ)-mediated retinal pathology from age-related changes
Age-related macular degeneration (AMD) is the commonest cause of irreversible blindness in developed societies. AMD coinci...
Edaravone-Dexborneol slows down pathological progression and cognitive decline via inhibiting S100A9 in APPswe/PS1dE9 mice
Edaravone-Dexborneol slows down pathological progression and cognitive decline via inhibiting S100A9 in APPswe/PS1dE9 mice
Edaravone-Dexborneol (EDB) presents therapeutic effects due to its anti-inflammatory, antioxidant and anti-apoptotic prope...
Computerized decision support to optimally funnel patients through the diagnostic pathway for dementia
Computerized decision support to optimally funnel patients through the diagnostic pathway for dementia
The increasing prevalence of dementia and the introduction of disease-modifying therapies (DMTs) highlight the need for ef...
Alzheimer’s disease-specific transcriptomic and epigenomic changes in the tryptophan catabolic pathway
Alzheimer’s disease-specific transcriptomic and epigenomic changes in the tryptophan catabolic pathway
Neurodegenerative disorders, including Alzheimer’s disease (AD), have been linked to alterations in tryptophan (TRP)...
Neuropsychiatric symptoms and lifelong mental activities in cerebral amyloid angiopathy – a cross-sectional study
Neuropsychiatric symptoms and lifelong mental activities in cerebral amyloid angiopathy – a cross-sectional study
While several studies in cerebral amyloid angiopathy (CAA) focus on cognitive function, data on neuropsychiatric symptoms ...
Updated safety results from phase 3 lecanemab study in early Alzheimer’s disease
Updated safety results from phase 3 lecanemab study in early Alzheimer’s disease
Alzheimer disease (AD) is a major health problem of aging, with tremendous burden on healthcare systems, patients, and fam...
Plasma biomarkers increase diagnostic confidence in patients with Alzheimer’s disease or frontotemporal lobar degeneration
Plasma biomarkers increase diagnostic confidence in patients with Alzheimer’s disease or frontotemporal lobar degeneration
The recent development of techniques to assess plasma biomarkers has changed the way the research community envisions the ...
Whole-brain modeling of the differential influences of amyloid-beta and tau in Alzheimer’s disease
Whole-brain modeling of the differential influences of amyloid-beta and tau in Alzheimer’s disease
Alzheimer’s disease is a neurodegenerative condition associated with the accumulation of two misfolded proteins, amy...
The age-specific comorbidity burden of mild cognitive impairment: a US claims database study
The age-specific comorbidity burden of mild cognitive impairment: a US claims database study
Identifying individuals with mild cognitive impairment (MCI) who are likely to progress to Alzheimer’s disease and r...
Exploring shared neural substrates underlying cognition and gait variability in adults without dementia
Exploring shared neural substrates underlying cognition and gait variability in adults without dementia
High gait variability is associated with neurodegeneration and cognitive impairments and is predictive of cognitive impair...
Clinical outcomes up to 9 years after [18F]flutemetamol amyloid-PET in a symptomatic memory clinic population
Clinical outcomes up to 9 years after [18F]flutemetamol amyloid-PET in a symptomatic memory clinic population
Previous studies demonstrated increases in diagnostic confidence and change in patient management after amyloid-PET. Howev...
Estimating attrition in mild-to-moderate Alzheimer’s disease and mild cognitive impairment clinical trials
Estimating attrition in mild-to-moderate Alzheimer’s disease and mild cognitive impairment clinical trials
Participant retention is a key factor that affects clinical trial integrity. Trial protocols estimate attrition as a funct...
Neuronal transcriptome, tau and synapse loss in Alzheimer’s knock-in mice require prion protein
Neuronal transcriptome, tau and synapse loss in Alzheimer’s knock-in mice require prion protein
Progression of Alzheimer’s disease leads to synapse loss, neural network dysfunction and cognitive failure. Accumula...
Health-related quality of life in subjective cognitive decline and mild cognitive impairment: a longitudinal cohort analysis
Health-related quality of life in subjective cognitive decline and mild cognitive impairment: a longitudinal cohort analysis
Health-related quality of life (HR-QoL) is an important outcome for patients and crucial for demonstrating the value of ne...
CSF biomarker analysis of ABCA7 mutation carriers suggests altered APP processing and reduced inflammatory response
CSF biomarker analysis of ABCA7 mutation carriers suggests altered APP processing and reduced inflammatory response
The Alzheimer’s disease (AD) risk gene ABCA7 has suggested functions in lipid metabolism and the immune system. Rare...